Clinical trialNCT06923527RecruitingPhase 2Interventional

Circulating Tumor DNA

SponsorYale UniversityEnrollment50ER+ Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mariya Rozenblit, MD
Yale University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Yale University
New Haven, Connecticut, United States
Mariya Rozenblit, MD
Recruiting
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Katia Khoury, MD
Recruiting
Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, Maryland, United States
Jenna Canzoniero, MD
Not, yet, recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Ilana M Schlam Camhi, MD MPH
Recruiting
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States
Jesus Anampa, MD
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Julia Foldi, MD PhD
Not, yet, recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Carlos H Barcenas, MD MSc
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Elacestrant →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2025
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 29 Jun 2026
Registered enrollment: 50
Registry id: NCT06923527

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.